/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Uromigos
  2. Episode 520: ESMO 2026 Preview
Episode 520: ESMO 2026 Preview

Episode 520: ESMO 2026 Preview

The Uromigos · Oct 12, 2026

The Uromigos preview ESMO 2026, evaluating key trials across prostate, kidney, and bladder cancer, focusing on perioperative therapies.

Frontline Kidney Cancer Triplets Fail Due to Cumulative Toxicity and Delivery Limitations

Combining three mechanisms in frontline kidney cancer failed in both LightSpark-012 and COSMIC trials. Adding more drugs increases toxicity, forcing dose holds and reductions that prevent adequate delivery across biologically relevant targets without precise patient selection.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago

Bispecific Antibodies Offer a Tolerable Path to Target Multiple Oncologic Mechanisms Simultaneously

Multi-drug triplets often fail due to compounded toxicities that prevent complete dosing. Bispecific antibodies that hit two targets, such as VEGF and PD-1, may bypass delivery hurdles and create a tolerable backbone for future combination regimens.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago

Refractory Kidney Cancer Doublets Require Balancing Tumor Shrinkage Against Added Toxicity Without OS

When refractory kidney cancer regimens lack overall survival advantages, clinicians cannot justify universal doublet escalation over monotherapy. Treating physicians must weigh the non-survival benefits of higher response rates against subjecting patients to the increased toxicities of multi-drug regimens.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago

Kidney Cancer Lacks Granular Clinical Stratification to Guide Therapy Escalation

Unlike prostate cancer, kidney cancer management currently lacks validated high- and low-volume criteria to guide treatment intensity. Clinicians recognize variations in disease pace, metastatic sites, and synchronous versus metachronous timing, but still treat patients uniformly in trials.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago

Shorter Neoadjuvant ADC Regimens Challenge Extended Perioperative Treatment Cycles in Bladder Cancer

Volga demonstrated overall survival benefits using only three neoadjuvant cycles of enfortumab vedotin combined with durvalumab. This finding questions whether patients truly need the extensive nine cycles delivered in Keynote-905, igniting debates over balancing oncologic cure against toxicity and healthcare costs.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago

Real-World Toxicity Already Forces Bladder Cancer Patients to Abandon Prolonged ADC Cycles

In clinical practice and clinical trial arms planned for nine perioperative cycles of EV-pembrolizumab, most patients fail to complete therapy due to adverse events. Consequently, real-world clinicians already administer de-escalated regimens resembling shorter three-cycle protocols out of necessity.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago

Investigator-Initiated Trials Are Essential to Test Treatment De-Escalation That Pharma Avoids

Pharmaceutical sponsors typically lack commercial incentives to fund non-inferiority trials testing shorter durations or treatment cessation. Academic groups must step forward to lead discontinuation studies, such as stopping immunotherapy after stable disease, which offer significant quality-of-life benefits.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago

High-Risk Localized Prostate Cancer Benefits Most From Intensified AR-Targeted Therapy

Trial evidence across STAMPEDE and ENZARAD suggests systemic treatment intensification primarily aids localized prostate cancer patients with very high-risk disease, such as conventional N1 status. Broad high-risk classifications remain too heterogeneous to justify intensified AR pathway inhibition for everyone.

Episode 520: ESMO 2026 Preview thumbnail

Episode 520: ESMO 2026 Preview

The Uromigos·a month ago